Therapy-Related Myeloid Neoplasm: Biology and Mechanistic Aspects of Malignant Progression

被引:2
作者
Travaglini, Serena [1 ,2 ]
Marinoni, Massimiliano [2 ]
Visconte, Valeria [3 ]
Guarnera, Luca [2 ]
机构
[1] Univ Roma Tor Vergata, Dept Expt Med, I-00133 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Biomed & Prevent, I-00133 Rome, Italy
[3] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44195 USA
关键词
Therapy-related Myeloid Neoplasm; t-MN; Myeloid Neoplasm post cytotoxic therapy; MN-pCT; WORLD-HEALTH-ORGANIZATION; LI-FRAUMENI-SYNDROME; CLONAL HEMATOPOIESIS; TP53; MUTATIONS; MYELODYSPLASTIC SYNDROME; STEM-CELLS; LEUKEMIA; SUSCEPTIBILITY; CANCER; RISK;
D O I
10.3390/biomedicines12051054
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Therapy-related myeloid neoplasms (t-MN) arise after a documented history of chemo/radiotherapy as treatment for an unrelated condition and account for 10-20% of myelodysplastic syndromes and acute myeloid leukemia. T-MN are characterized by a specific genetic signature, aggressive features and dismal prognosis. The nomenclature and the subsets of these conditions have changed frequently over time, and despite the fact that, in the last classification, they lost their autonomous entity status and became disease qualifiers, the recognition of this feature remains of major importance. Furthermore, in recent years, extensive studies focusing on clonal hematopoiesis and germline variants shed light on the mechanisms of positive pressure underpinning the rise of driver gene mutations in t-MN. In this manuscript, we aim to review the evolution of defining criteria and characteristics of t-MN from a clinical and biological perspective, the advances in mechanistic aspects of malignant progression and the challenges in prevention and management.
引用
收藏
页数:18
相关论文
共 125 条
[1]   Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia [J].
Aldoss, Ibrahim ;
Zhang, Jianying ;
Pillai, Raju ;
Shouse, Geoffrey ;
Sanchez, James F. ;
Mei, Matthew ;
Nakamura, Ryotaro ;
Stein, Anthony S. ;
Forman, Stephen J. ;
Marcucci, Guido ;
Pullarkat, Vinod .
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) :E45-E48
[2]   Genetic susceptibility to iatrogenic malignancy [J].
Allan, JM ;
Rabkin, CS .
PHARMACOGENOMICS, 2005, 6 (06) :615-628
[3]   Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia [J].
Allan, JM ;
Wild, CP ;
Rollinson, S ;
Willett, EV ;
Moorman, AV ;
Dovey, GJ ;
Roddam, PL ;
Roman, E ;
Cartwright, RA ;
Morgan, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11592-11597
[4]   Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours [J].
Almanza-Huante, Emmanuel ;
Bataller, Alex ;
Urrutia, Samuel ;
Gener-Ricos, Georgina ;
Briski, Robert Edward ;
Kanagal-Shamanna, Rashmi ;
Lu, Karen H. ;
Westin, Shannon N. ;
Yap, Timothy A. ;
Takahashi, Koichi ;
Ravandi, Farhad ;
Alvarado, Yesid ;
Kadia, Tapan ;
Sasaki, Koiji ;
Kantarjian, Hagop M. ;
Garcia-Manero, Guillermo .
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) :E25-E29
[5]  
APREA THERAPEUTICS, 2021 AM SOC HEM ASH
[6]   International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert P. ;
Borowitz, Michael J. ;
Calvo, Katherine R. ;
Kvasnicka, Hans-Michael ;
Wang, Sa A. ;
Bagg, Adam ;
Barbui, Tiziano ;
Branford, Susan ;
Bueso-Ramos, Carlos E. ;
Cortes, Jorge E. ;
Dal Cin, Paola ;
DiNardo, Courtney D. ;
Dombret, Herve ;
Duncavage, Eric J. ;
Ebert, Benjamin L. ;
Estey, Elihu H. ;
Facchetti, Fabio ;
Foucar, Kathryn ;
Gangat, Naseema ;
Gianelli, Umberto ;
Godley, Lucy A. ;
Gokbuget, Nicola ;
Gotlib, Jason ;
Hellstrom-Lindberg, Eva ;
Hobbs, Gabriela S. ;
Hoffman, Ronald ;
Jabbour, Elias J. ;
Kiladjian, Jean-Jacques ;
Larson, Richard A. ;
Le Beau, Michelle M. ;
Loh, Mignon L. -C. ;
Lowenberg, Bob ;
Macintyre, Elizabeth ;
Malcovati, Luca ;
Mullighan, Charles G. ;
Niemeyer, Charlotte ;
Odenike, Olatoyosi M. ;
Ogawa, Seishi ;
Orfao, Alberto ;
Papaemmanuil, Elli ;
Passamonti, Francesco ;
Porkka, Kimmo ;
Pui, Ching-Hon ;
Radich, Jerald P. ;
Reiter, Andreas ;
Rozman, Maria ;
Rudelius, Martina ;
Savona, Michael R. .
BLOOD, 2022, 140 (11) :1200-1228
[7]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[8]  
Awada H, 2021, BLOOD, V138, P1885, DOI 10.1182/blood.2020010603
[9]   Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders [J].
Awada, Hussein ;
Gurnari, Carmelo ;
Visconte, Valeria ;
Durmaz, Arda ;
Kuzmanovic, Teodora ;
Awada, Hassan ;
Tu, Zheng Jin ;
Cook, James R. ;
Bolwell, Brian J. ;
Sobecks, Ronald ;
Kalaycio, Matt ;
Bosler, David ;
Maciejewski, Jaroslaw P. .
LEUKEMIA, 2024, 38 (06) :1266-1274
[10]   Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up [J].
Baliakas, Panagiotis ;
Tesi, Bianca ;
Wartiovaara-Kautto, Ulla ;
Stray-Pedersen, Asbjorg ;
Friis, Lone Smidstrup ;
Dybedal, Ingunn ;
Hovland, Randi ;
Jahnukainen, Kirsi ;
Raaschou-Jensen, Klas ;
Ljungman, Per ;
Rustad, Cecilie F. ;
Lautrup, Charlotte K. ;
Kilpivaara, Outi ;
Kittang, Astrid Olsnes ;
Gronbaek, Kirsten ;
Cammenga, Jorg ;
Hellstrom-Lindberg, Eva ;
Andersen, Mette K. .
HEMASPHERE, 2019, 3 (06)